Younger women with endocrine-sensitive breast cancer benefit from adjuvant endocrine therapy. However,  choosing the right endocrine therapy for the youngest women with endocrine-sensitive breast cancer remains a challenge for clinicians.

It is difficult to balance the expected benefits of therapy with the known burden of toxicities associated with estrogen deprivation therapies. In your opinion, what is right endocrine therapy for young women with endocrine-sensitive breast cancer?